Vínculo: A Digital Intervention for Anxiety, Depression, and Insomnia Symptoms (VINCULO-ADI)
Vínculo: A Randomized Controlled Trial of a Guided Digital Intervention for Anxiety, Depression, and Insomnia Symptoms
Insomnia, anxiety, and depression are common mental health problems that frequently occur together. Psychological interventions that address shared processes underlying these symptoms may offer an accessible way to improve mental health and sleep.
This study will evaluate the effectiveness of Vínculo, an eight-week, guided digital psychological intervention for adults experiencing clinically significant symptoms of insomnia, anxiety, and/or depression.
Approximately 305 adults living in Brazil will be randomly assigned to one of two groups. The experimental group will receive Vínculo, a psychological intervention delivered through a WhatsApp chatbot that combines acceptance and commitment therapy, behavioral activation, and behavioral strategies for sleep. The comparison group will receive an eight-week digital psychoeducation program covering mental health, emotions, sleep, and healthy lifestyle habits.
Both groups will receive structured content through WhatsApp, three individual videoconference sessions with a psychologist, and access to asynchronous psychological support during the intervention.
The main objective is to determine whether Vínculo is more effective than digital psychoeducation in reducing insomnia severity, depressive symptoms, and anxiety symptoms after eight weeks. Participants will also be assessed three and six months after the intervention to examine whether improvements are maintained. Additional assessments will examine daily functioning and psychological processes related to treatment outcomes.
調査の概要
状態
詳細な説明
This study is a fully remote, open-label, two-arm, parallel-group randomized controlled trial designed to evaluate the efficacy of Vínculo, a guided digital transdiagnostic psychological intervention, compared with an active digital psychoeducation control condition.
The study will enroll approximately 305 adults aged 18-59 years living in Brazil who report clinically significant symptoms in at least one of three domains: insomnia, depression, or anxiety. Eligibility will be established through electronic screening followed by a structured clinical assessment. A formal psychiatric diagnosis will not be required for inclusion.
After baseline assessment, participants will be randomized in a 1:1 ratio using computer-generated, randomly permuted blocks of varying sizes. Randomization will be stratified according to eight possible baseline symptom profiles, defined by the presence or absence of clinically significant insomnia, depression, and anxiety symptoms. Allocation will be implemented through REDCap.
The experimental intervention is based on process-based therapy and integrates components of acceptance and commitment therapy, behavioral activation, and behavioral strategies for insomnia. Therapeutic content will address emotional awareness, experiential avoidance, mindfulness, values clarification, committed action, behavioral activation, acceptance, cognitive defusion, sleep-related behaviors, and relapse prevention. Behavioral sleep strategies will be introduced in Week 4 and will not include sleep restriction.
The active control condition will provide structured psychoeducation about mental health, emotional symptoms, sleep, and healthy lifestyle habits without introducing the specific therapeutic techniques of the experimental intervention.
Both conditions will last eight weeks. Structured digital content will be delivered through WhatsApp three times weekly, with reminders on alternate days. Participants in both groups will receive three individual videoconference sessions with a psychologist and access to asynchronous professional support on business days. The content of professional support will be specific to each assigned condition.
The three co-primary outcomes are insomnia severity, depressive symptoms, and anxiety symptoms, assessed one week after completion of the eight-week intervention using the Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7), respectively.
Secondary assessments will examine symptom severity at three- and six-month follow-ups, functional impairment, clinical response, behavioral activation, and psychological flexibility. Exploratory assessments will address anhedonia and working alliance.
The primary analyses will compare treatment groups while accounting for baseline symptom severity. The study will also investigate treatment effects across different baseline symptom presentations and evaluate changes in psychological processes associated with clinical outcomes.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Renatha El Rafihi-Ferreira, PhD
- 電話番号:+5511991841188
- メール:protocolovinculo@gmail.com
研究場所
-
-
São Paulo
-
São Paulo、São Paulo、ブラジル、05508-030
- Institute of Psychology, University of São Paulo
-
コンタクト:
- Renatha El Rafihi-Ferreira, PhD
- 電話番号:+5511991841188
- メール:protocolovinculo@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 18 to 59 years.
- Clinically significant symptoms in at least one of the following domains at screening:
- Insomnia: Insomnia Severity Index (ISI) score ≥11;
- Depression: Patient Health Questionnaire-9 (PHQ-9) score ≥10;
- Anxiety: Generalized Anxiety Disorder-7 (GAD-7) score ≥10.
- Residence in Brazil.
- Ability to read and understand written Portuguese.
- Regular access to WhatsApp on a personal device.
- Willingness and availability to participate in the intervention and complete the scheduled study assessments.
- Provision of electronic informed consent.
Exclusion Criteria:
- Current diagnosis of bipolar disorder or psychotic disorder, or severe suicide risk.
- Substance use disorder that would substantially interfere with participation in the intervention or completion of study assessments.
- Severe and unstable neurological or medical conditions, such as dementia or advanced-stage cancer.
- Night-shift work that cannot be reorganized.
- Significant cognitive impairment that would hinder participation in the digital intervention.
- Unavailability to participate in the intervention or complete the scheduled study assessments.
- Use of sleep medication, either regularly or intermittently, without a stable medication use pattern for at least 2 months before enrollment, including recent initiation or substantial changes in the regimen.
- Use of antidepressants or other psychotropic medications intended for regular use without a stable regimen for at least 1 month following a dose adjustment or 2 months following initiation of a new medication.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Vínculo Digital Intervention
Participants will receive Vínculo, an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. The intervention integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep strategies. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days (Monday to Friday). |
Vínculo is an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. Based on process-based therapy, it integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep regulation. Components include mindfulness, acceptance, cognitive defusion, values clarification, committed action, and behavioral activation. Sleep-related content is addressed throughout the intervention, including psychoeducation, stimulus control, a consistent wake time, daytime activity, morning natural light exposure, and a wind-down routine. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days. |
|
アクティブコンパレータ:Digital Psychoeducation
Participants will receive an eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques used in the experimental intervention. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days (Monday to Friday), limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement. |
An eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides structured information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques of the experimental intervention. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days. Professional support is limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Insomnia Symptom Severity (Insomnia Severity Index - ISI)
時間枠:One week after completion of the 8-week intervention
|
The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. The primary outcome is the ISI total score at post-treatment, adjusted for baseline severity. |
One week after completion of the 8-week intervention
|
|
Depressive Symptom Severity (Patient Health Questionnaire-9 - PHQ-9)
時間枠:One week after completion of the 8-week intervention
|
The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. The primary outcome is the PHQ-9 total score at post-treatment, adjusted for baseline severity. |
One week after completion of the 8-week intervention
|
|
Anxiety Symptom Severity (Generalized Anxiety Disorder-7 - GAD-7)
時間枠:One week after completion of the 8-week intervention
|
The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The primary outcome is the GAD-7 total score at post-treatment, adjusted for baseline severity. |
One week after completion of the 8-week intervention
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Insomnia Symptom Severity at Follow-up (Insomnia Severity Index - ISI)
時間枠:3 and 6 months after completion of the 8-week intervention
|
The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. ISI total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity. |
3 and 6 months after completion of the 8-week intervention
|
|
Depressive Symptom Severity at Follow-up (Patient Health Questionnaire-9 - PHQ-9)
時間枠:3 and 6 months after completion of the 8-week intervention
|
The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. PHQ-9 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity. |
3 and 6 months after completion of the 8-week intervention
|
|
Anxiety Symptom Severity at Follow-up (Generalized Anxiety Disorder-7 - GAD-7)
時間枠:3 and 6 months after completion of the 8-week intervention
|
The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. GAD-7 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity. |
3 and 6 months after completion of the 8-week intervention
|
|
Functional Impairment (Sheehan Disability Scale - SDS)
時間枠:One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Sheehan Disability Scale (SDS) is a three-item self-report measure assessing functional impairment in work or school, social life, and family life or home responsibilities. Each domain is scored from 0 to 10, with a total score ranging from 0 to 30. Higher scores indicate greater functional impairment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Behavioral Activation (Behavioral Activation for Depression Scale - Short Form, BADS-SF)
時間枠:Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Behavioral Activation for Depression Scale - Short Form (BADS-SF) is a nine-item self-report measure assessing behavioral activation and avoidance. Total scores range from 0 to 54, with higher scores indicating greater behavioral activation. Changes in behavioral activation will be evaluated across the scheduled assessments. |
Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Psychological Flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes - CompACT)
時間枠:Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT) is a 23-item self-report measure assessing psychological flexibility through openness to experience, behavioral awareness, and valued action. Total scores range from 0 to 138, with higher scores indicating greater psychological flexibility. |
Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Clinical Response in Insomnia Symptoms (ISI)
時間枠:One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Clinical response in insomnia symptoms will be defined as a reduction of at least 8 points in the Insomnia Severity Index (ISI) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Clinical Response in Depressive Symptoms (PHQ-9)
時間枠:One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Clinical response in depressive symptoms will be defined as a reduction of at least 50% in the Patient Health Questionnaire-9 (PHQ-9) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Clinical Response in Anxiety Symptoms (GAD-7)
時間枠:One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Clinical response in anxiety symptoms will be defined as a reduction of at least 50% in the Generalized Anxiety Disorder-7 (GAD-7) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Anhedonia (Snaith-Hamilton Pleasure Scale - SHAPS)
時間枠:One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item self-report questionnaire assessing anhedonia, defined as a reduced capacity to experience pleasure. Using conventional dichotomous scoring, total scores range from 0 to 14, with higher scores indicating greater anhedonia. Changes in anhedonia will be evaluated as an exploratory outcome. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Therapeutic Alliance (Working Alliance Inventory for Guided Internet Interventions - WAI-I)
時間枠:Week 4 and one week after completion of the 8-week intervention
|
The Working Alliance Inventory for Guided Internet Interventions (WAI-I) is a self-report measure assessing the therapeutic alliance in guided internet-based psychological interventions, including agreement on therapeutic goals, agreement on tasks, and the therapeutic bond. Higher scores indicate a stronger therapeutic alliance. Therapeutic alliance will be evaluated as an exploratory outcome. |
Week 4 and one week after completion of the 8-week intervention
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Renatha El Rafihi-Ferreira, PhD、University of Sao Paulo
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CISM-VINCULO-ADI
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data sharing has not yet been determined. Study data will be securely stored, and access will be restricted to authorized research personnel in accordance with institutional policies, ethical approvals, and Brazilian data protection legislation. The possibility of sharing de-identified participant data for scientific purposes will be evaluated in accordance with applicable ethical and institutional requirements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。